SCM
NGNE icon

Sterling Capital Management’s Neurogene NGNE Stock Holding History

Sterling Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.54K Sell
374
-193
-34% -$3.74K ﹤0.01% 2521
2025
Q4 		$11.7K Sell
567
-112
-16% -$2.79K ﹤0.01% 2532
2025
Q3 		$11.8K Buy
679
+413
+155% +$8.29K ﹤0.01% 2402
2025
Q2 		$3.98K Buy
266
+163
+158% +$2.56K ﹤0.01% 2632
2025
Q1 		$1.21K Sell
103
-68
-40% -$1.18K ﹤0.01% 2754
2024
Q4 		$3.91K Buy
171
+149
+677% +$5.54K ﹤0.01% 2563
2024
Q3 		$923 Buy
+22
New +$853 ﹤0.01% 2576
2015
Q2 		– Sell
-650
Closed -$107K – 913
2015
Q1 		$107K Hold
650
– – ﹤0.01% 856
2014
Q4 		$97K Sell
650
-86
-12% -$12.2K ﹤0.01% 899
2014
Q3 		$98K Hold
736
– – ﹤0.01% 882
2014
Q2 		$139K Sell
736
-442
-38% -$85.3K ﹤0.01% 865
2014
Q1 		$300K Buy
+1,178
New +$303K ﹤0.01% 860

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Sterling Capital Management's NGNE Position: Q1 2026 in Review

Sterling Capital Management reduced its Neurogene (NGNE) stake by 34% in Q1 2026, selling an estimated $3.74K and leaving 374 shares worth $7.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Sterling Capital Management first reported a position in NGNE in Q1 2014 and has held it in 12 quarters since. The position peaked at $300K in Q1 2014. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Sterling Capital Management held 374 shares of Neurogene worth $7.54K as of Q1 2026.
  • Sterling Capital Management sold 193 Neurogene shares in Q1 2026, an estimated $3.74K.
  • Neurogene made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2521 holding.
  • Sterling Capital Management first reported a position in Neurogene in Q1 2014 and has held it in 12 quarters since.
  • Sterling Capital Management's Neurogene position peaked at $300K in Q1 2014.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.